Mumbai, India, January 31, 2023 – Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUN PHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) today announced that it has acquired three brands viz. Disperzyme® (Trypsin BP 96 mg, Bromelain 180 mg & Rutoside Trihydrate 200 mg), Disperzyme-CD® (Trypsin BP 48 mg, Bromelain 90 mg & Rutoside Trihydrate 100 mg) and Phlogam® (Trypsin BP 48 mg, Bromelain 90 mg & Rutoside Trihydrate 100 mg) from Aksigen Hospital Care (“Aksigen”), a Mumbai based research-driven healthcare entity with more than two decades of experience in the healthcare field. All the brands are approved by the Drugs Controller General of India (“DCGI”) for post-operative inflammation in patients undergoing minor surgery and dental procedures.
All the brands are approved by the Drugs Controller General of India (“DCGI”) for post-operative inflammation in patients undergoing minor surgery and dental procedures.
Disperzyme® and Phlogam® are the first enzyme-bioflavonoid combination of Trypsin, Bromelain, and Rutoside (“TBR”) to complete a clinical study in India and get DCGI approval. The brands were registered and launched in India by Aksigen in 2013.
Kirti Ganorkar, CEO-India business, Sun Pharma, said, “The addition of Disperzyme® and Phlogam® further strengthens our anti-inflammatory portfolio. This systemic enzyme therapy combination is being used to control edema and it speeds up the healing process. In a comparative clinical trial in India, the brands provided significantly better control and resolution of post-operative pain and inflammation.”
The overall market of proteolytic enzymes for healing, pain, and edema in India is around Rs.500 crores (as per IQVIA data MAT Nov 2022).